Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

CTNM

Contineum Therapeutics Inc.

Jun 25 • 04:00PM ET

19.93

Dollar change +0.74
Percentage change 3.86	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: SCHA VTI VXF VTWO VTWG VTWV

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	61.82%	Shs Outstand	23.40M	Perf Week	24.56%
Market Cap	512.60M	Forward P/E	-	EPS next Y	-1.57	Insider Trans	0.00%	Shs Float	9.82M	Perf Month	23.71%
Income	-	PEG	-	EPS next Q	-0.35	Inst Own	12.78%	Short Float	5.76%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-4172.22%	Inst Trans	-	Short Ratio	5.33	Perf Half Y	-
Book/sh	-2.94	P/B	-	EPS next Y	14.32%	ROA	-	Short Interest	0.57M	Perf Year	-
Cash/sh	4.58	P/C	4.35	EPS next 5Y	-	ROE	-	52W Range	13.27 - 20.83	Perf YTD	29.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-4.30%	Beta	-
Dividend TTM	-	Quick Ratio	19.20	Sales past 5Y	0.00%	Gross Margin	-	52W Low	50.19%	ATR (14)	1.49
Dividend Ex-Date	-	Current Ratio	19.20	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	66.56	Volatility	14.99% 9.07%
Employees	31	Debt/Eq	-	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	28.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	-	Payout	-	Rel Volume	1.28	Prev Close	19.19
Sales Surprise	-	EPS Surprise	-218.39%	Sales Q/Q	-	Earnings	May 16 AMC	Avg Volume	105.94K	Price	19.93
SMA20	20.15%	SMA50	25.10%	SMA200	25.55%	Trades		Volume	136,122	Change	3.86%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-30-24	Initiated	Stifel	Buy	$29
Apr-30-24	Initiated	RBC Capital Mkts	Outperform	$30
Apr-30-24	Initiated	Morgan Stanley	Overweight	$25

Jun-24-24 04:05PM	Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors (Business Wire)
Jun-04-24 04:05PM	Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference (Business Wire)
Jun-03-24 04:05PM	Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary (Business Wire)
May-20-24 04:05PM	Contineum Therapeutics Announces Appointment of Troy Ignelzi to Board of Directors (Business Wire)
May-16-24 04:05PM	Contineum Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
09:02PM	Loading…
Apr-04-24 09:02PM	Contineum Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company, which focuses on discovering and developing novel, oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. The company was founded by Daniel S. Lorrain on May 9, 2017 and is headquartered in San Diego, CA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CTNM

Contineum Therapeutics Inc.

Upgrade your FINVIZ experience